Open AccessP1088: UPDATED DATA FROM A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN COMBINED WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
Author(s) -
Locatelli F.,
Luisi F.,
Pianovski M.,
Salvino M. A.,
Fagioli F.,
Epelman S.,
Britto De Abreu Lima L.,
Norris R.,
Odone Filho V.,
Zecca M.,
Favre C.,
Kobayashi R.,
Koga Y.,
Sidi Y.,
Zhou X.,
Bai X.,
Campana F.,
Leonard E. J.,
Franklin A. R.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847220.98181.15
Subject(s) - brentuximab vedotin , medicine , dacarbazine , tolerability , oncology , vinblastine , adverse effect , regimen , discontinuation , chemotherapy regimen , chemotherapy , lymphoma , cd30